Nilgün BAL, Şenel ACAR TOT, Aylin YAZICI, Kemal YAZICI, Lülüfer TAMER

Altered levels of malondialdehyde and vitamin e in major depressive disorder and generalized anxiety disorder

Amaç: Reaktif oksijen türleri (ROT) bazı nöropsikiyatrik rahatsızlıklarda rol oynayabilirler. İmmün-inflamatuvar aktivasyon, monoamin katabolizmasında artış ve lipid bileşenlerinde ortaya çıkan anormalliklerin aşırı ROT üretimine ve lipid peroksidasyonuna neden olduğuna dair kanıtlar bulunmaktadır. Bu fenomenler, majör depresyon ve yaygın anksiyete bozukluğunun patofizyolojisi ile ilişkili olabilir. Malondialdehid (MDA) lipid peroksidasyonunun son ürünüdür. E vitamininin lipid peroksidasyonuna karşı önemli bir antioksidan molekül olduğu ileri sürülmektedir. Bu çalışmanın amacı, oksijen radikallerinin majör depresif bozukluk ve yaygın anksiyete bozukluğunun etiyolojisindeki rolünü belirlemektir. Yöntem: Majör depresif bozukluk tanısı alan 42 hasta ve yaygın anksiyete bozukluğu tanısı (YAB) alan 37 hasta ile sağlıklı kontrol grubunu oluşturan 38 kişinin plazma MDA ve E vitamini düzeyleri ölçüldü. Tüm gruplara Hamilton Depresyon Ölçeği (HDÖ) ve Hamilton Anksiyete Ölçeği (HAÖ) uygulandı. Bulgular: Majör depresif bozukluk ve yaygın anksiyete bozukluğu tanısı alan kişilerin, sağlıklı kontrol grubuna kıyasla daha yüksek MDA ve daha düşük E vitamini düzeylerine sahip oldukları saptandı. Hasta ve kontrol grupları arasındaki fark istatistiksel olarak anlamlı bulundu. Sonuç: Bulgularımız oksidatif stresin depresyon ve anksiyete semptomlarında etkili olabileceğini desteklemektedir. Sonuç olarak, serbest radikal hasarı ve antioksidan savunma sistemindeki yetersizlik majör depresif bozukluk ve yaygın anksiyete bozukluğunun etiyolojisinde önemli rol alabilir.

Majör depresif bozukluk ve yaygın anksiyete bozukluğunda malondialdehid ve E vitamini düzeyleri

Altered levels of malondialdehyde and vitamin E in major depressive disorder and generalized anxiety disorder Introduction: Reactive oxygen species (ROS) may play a role in some neuropsychiatric disorders. There is some evidence that the activation of immune-inflammatory processes, an increase in monoamines catabolism and abnormalities in lipid compounds may cause overproduction of ROS and lipid peroxidation. These phenomena may be related to pathophysiology of major depressive disorder and generalized anxiety disorder. Malondialdehyde (MDA) is the end product of lipid peroxidation. Vitamin E is thought to play an important role as an antioxidant against lipid peroxidation. This study aims to investigate the role of oxygen radicals in the etiology of major depressive disorder and generalized anxiety disorder. Method: Plasma MDA and vitamin E levels of patients with major depressive disorder (n=42) and generalized anxiety disorder (n=37) were compared with healthy controls (n=38). To assess depressive symptoms and anxiety symptoms, Hamilton Depression Scale and Hamilton Anxiety Scale were applied. Results: Patients with major depressive disorder and generalized anxiety disorder had higher MDA and lower vitamin E levels than those of healthy controls. Differences between the patient and the control groups according to these two parameters were found statistically significant. Conclusion: Our results support the hypothesis that oxidative stress may affect depressive and anxiety symptoms. As a result, free radical damage and deficiency of antioxidant defence systems may have an important role in major depressive disorder and generalized anxiety disorder.

PDF

___

1. Lohr JB. Oxygen radicals and neuropsychiatric illnesses. Some speculations. Arch Gen Psychiatry 1991; 48:1097-1104.
2. Torun M, Yardım S, Gönenç A, Sargın H. Çeşitli kanser vakalarında serum MDA düzeyleri. Biyokimya Dergisi 1995; 20:1-7. (Article in Turkish)
3. Draper H, McGirr LG, Hadley M. The metabolism of malondialdehyde. Lipids 1986; 21:305-307.
4. Rigucci S, Serafini G, Pompili M, Kotzalidis GD, Tatarelli R. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies. World J Biol Psychiatry 2010; 11:165-180.
5. Jesperger JA. Oxygen free radicals and brain function. Int J Neurosci 1991; 57:1-17.
6. Weber GF. The pathopsysiology of reactive oxygen intermediates in the central nervous system. Med Hypothesis 1994; 43:223- 230.
7. Sarandol A, Sarandol E, Eker SS, Erdinç S, Vatansever E, Kırlı S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative- antioxidative systems. Hum Psychopharmacol 2007; 22:67-73.
8. Özcan E, Güleç M, Özerol E, Polat R, Akyol Ö. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004; 19:89-95.
9. Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E. Oxidatif stress parameters after combined fluoxetine and acetylsalisilic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24:277-286.
10. Irwin M. Immun correlates of depression. Adv Exp Med Biol 1999; 461:1-24.
11. Maddock C, Pariante CM. How does stres affect you? An overview of stres, immunity, depression and disease. Epidemiol Psychiatr Soc 2001; 10:153-162.
12. Maes M, De Vos N, Pioli R, Wauters A, Neels H, Cristophe A. Lower serum vitamin E concentrations in major depression: another marker of lowered antioxidant defences in that illness. J Affect Disord 2000; 58:241-246.
13. Maes M, Smith RS. Fatty acids, cytokines and major depression. Biol Psychiatry 1998; 43:313-314.
14. Maes M, Cristophe A, Delange J, Neels H, Scharpe S, Meltzer HY. Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1996; 85:275-291.
15. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith ELP, Heier LA, Otcheretko V, Coplan JD, Shungu DC. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T 1 H MRS imaging study. NMR Biomed 2009; 251-258.
16. Kuloglu M, Atmaca M, Tezcan E, Gecici Ö, Tunckol H, Ustundag B. Antioxidant enzyme and malondialdehyde levels in patients with obsessive compulsive disorder. Neuropsychobiology 2002; 46:27-32.
17. Kuloğlu M, Atmaca M, Tezcan E, Ustundağ B, Bulut S. Antioxidant enzyme and malondialdehyde levels in patients with panic disorder. Neuropsychobiology 2002; 46:186-189.
18. Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H. Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Clin Neurosci 2004; 254:231-235.
19. Kessler RC, Gruber M, Hettema JM, Huang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disordes in the National Comorbidity Survey follow-up. Psychol Med 2008; 38:365-374.
20. Pirkola SP; Isometsa E, Suvisaari J, Aro H, Joukamaa M, Poikoloinan K, Koskinen S, Aromaa A, Lonnqvist SK. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population-results from the Health 2000 study. Soc Psychiatry Psychiatr Epidemiol. 2005; 40:1-10.
21. Hettema JM. What is the genetic relationship between anxiety and depression? Am J Med Genet C Semin Med Genet 2008; 148:140-146.
22. Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N, Özbay H. Hamilton Depresyon Derecelendirme Ölçeğinin (HDDÖ) geçerliliği, güvenirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4:251-259 (Article in Turkish).
23. Yazıcı MK, Demir B, Tanrıverdi N, Karaağaoğlu E, Yolaç P. Hamilton Anksiyete Değerlendirme Ölçeği, değerlendiriciler arası güvenilirlik ve geçerlilik çalışması. Turk Psikiyatri Derg 1998; 9:114-117 (Article in Turkish).
24. Thibeault D, Su H, MacNamara E, Schipper HM. Isocratic rapid liquid chromatographic method for simultaneous determination of carotenoids, retinol, and tocopherols in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 15; 877:1077-1083.
25. Yagi K. Lipid peroxides and related radicals in clinical medicine: In Armstrong D. (Editor). Free Radicals in Diagnostic Medicine. Plenum Press: New York, 1994,1-15.
26. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001; 64:43-51.
27. Khanzode SD, Dakhake GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potantial antioxidant action of selective serotonin reuptake inhibitors. Redox Rep 2003; 8:365-370.
28. Galecki P, Szemraj J, Bienkiewicz M, Florkowski A, Galecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetin treatment. Pharmacol Rep 2009; 61:436-447.
29. Van-der-Vliet A, Bast A. Effect of oxidative stress on receptors and signal transmission. Chem Biol Interact 1992; 85:95-116.
30. Gorman JM, Hirschfeld RM, Ninan PT. New developments in the neurobiological basis of anxiety disorders. Psychopharmacol Bull 2002; 36 (Suppl.2):49-67.
31. Britt Sg, Chiu VW, Redpath GT, Vanderberg SR. Elimination of ascorbic acid-induced membrane lipid peroxidation and serotonin receptor loss by Trolox-C, a water soluble analogue of vitamin E. J Recept Res 1992; 12:181-200.
32. Nemeroff CB. Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002; 36 (Suppl.2):6-23.
33. Liu J, Wang X, Mori A. Immobilization stress-induced antioxidant defence changes in rat plasma: effect of treatment with reduced glutathione. Int J Biochem 1994; 26:511-517.
34. Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H. Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Clin Neurosci 2004; 254:231-235.
35. Shibata H, Kumagai S, Watanabe S, Suzuki T. Relationship of serum cholestrols and vitamin E to depressive status in the elderly. J Epidemiol 1999; 9:261-267.
36. Tiemeier H, Hofman A, Kiliaan AJ, Meijer J, Breteler MM. Vitamin E and depressive symptoms are not related: The Rotterdam Study. J Affact Disord 2002; 72:79-83.
37. Tietz NW. Clinical guide to laboratory tests. Philadelphia: WB Saunders Company, 1990.
38. Louw JA, Werbeck A, Louw ME, Kotze TJ, Cooper R, Labadarios D. Blood vitamin concentrations during the acute phase response. Crit Care Med 1992; 20:934-941.
39. Maes M, Meltzer HY. The serotonin hypothesis of major depression. Psychopharmacology: The Fourth Generation of Progress 1995;933-941.